The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias.

The article discusses new research and findings in the field of cardiovascular medicine, specifically focusing on dyslipidemias. The studies mentioned include the analysis of lipid parameters in infants and their predictive capabilities, the global distribution of atherogenic lipid levels, the effectiveness of bempedoic acid in lowering LDL-C, the development of oral PCSK9-lowering therapies, the use of base-editing therapy for PCSK9 gene targeting, the impact of pemafibrate on triglycerides and HDL-C, the association of elevated remnant cholesterol and triglycerides with mortality, the atherogenicity of triglyceride-rich lipoproteins compared to LDL-C, the development of a small molecule inhibitor for Lp(a) formation, the importance of inflammation in ASCVD risk, and the use of proteomics and lipidomics for risk prediction and individualized therapy. The article provides valuable insights into the understanding and treatment of dyslipidemias and their relationship to cardiovascular disease. [Extracted from the article]